Trial Profile

A Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 19 Dec 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olodanrigan (Primary)
Indications Diabetic neuropathies; Musculoskeletal pain; Neuropathic pain
Focus Therapeutic Use
Sponsors Spinifex Pharmaceuticals

Most Recent Events

25 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
10 Feb 2015 According to Spinifex Pharmaceuticals media release, intended initiation date is in mid 2015.
14 Apr 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com